(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

QIAGEN - SAMPLE TO OUTCOME

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

QIAGEN - SAMPLE TO OUTCOME

ST13

US500000079264394

Classe

9, 10, 42, 44

Pedido

79264394

Registro

6104156

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

27

Atualização mais recente

22/07/2025

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

9, 10, 42, 44

Data de depósito

09/05/2019

Data de registro

21/07/2020

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

21/07/2020

Última transação

22/07/2025

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

16

Localização do titular

DE

Examinador

MAJCHER HARTNETT, MEGAN

Unidade examinadora

N50

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

Qiagen GmbH

Representantes

Keith A. Weltsch Scully, Scott, Murphy & Presser, P.C.

Classificação técnica

Classes Nice

Classe 9Classe 10Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 9

Downloadable and recorded computer software for data and document management, medical teaching; downloadable and recorded computer software and related downloadable databases for use in preparing and managing nucleic acid and protein assay analysis and for managing quality control, validation, interpretation, reporting, clinical decision support, data management, integration with medical records, physician portals, laboratory networking, professional healthcare and trial matching services all related to molecular and genomic analysis; downloadable and recorded computer software, namely, evidence-based decision support software used as an aid in the interpretation of variants observed in genomic sequencing data; downloadable and recorded computer software for evaluation of genomic variants in the context of software for searching and allocating published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and/or clinical-trials; downloadable and recorded computer software for preparing, interpretation and managing of bioinformatics analyses, optionally combined with data management, graphical viewing and output options; downloadable and recorded computer programs and software for biological data mining; downloadable and recorded computer programs and software for developing bioinformatics database for others; bio-chips for research or scientific purposes; DNA-chips; RNA-chips; next-generation sequencing (NGS) data processor; bioinformatics data processor; computer hardware and downloadable and recorded computer software for collecting, storing, analyzing, visualizing, and interpreting bioinformatics, genomics, and phenomics data sets; computer hardware and downloadable and recorded computer software for the monitoring of pathogens; downloadable computer databases for bioinformatics, genomics, phenomics, microbiome, metagenomics, organism-and -pathogen-specific genotype records, and organism and pathogen-specific phenotype information; downloadable and recorded computer software for use in the integration, analysis and visualization of biomedically relevant information allowing users to explore compound, target, assay, biological pathway and disease information; downloadable and recorded computer software and databases for the analysis of genomes, exomes, targeted amplicons, transcriptomes, and epigenetic NGS sequencing data; downloadable and recorded computer software, software development tools, and visualization software modules, for analysis, discovery, verification, and validation of disease biomarkers

Classe 10

Medical diagnostic testing instruments for processing and analysis of genetic samples primarily for single-cell genomic, transcriptomic, or proteomic analysis; medical and diagnostic apparatus for testing DNA and RNA samples, using gene expression tests, gene expression profiling assays, genetic information and data, protein biomarkers, clinical data, and/or demographic information; testing apparatus for medical purposes for testing DNA and RNA samples sold as a unit with downloadable bioinformatics and machine learning algorithm software and medical data software to support treatment decisions; medical testing apparatus for testing DNA and RNA samples and quantifying biomarker levels and relative expression of host response genes; medical apparatus and instruments for detecting tumor cancer, heredity and genetic diseases; medical testing apparatus for samples of body fluids, tissue and organs; genome machine for medical purposes, namely, apparatus for DNA and RNA medical testing; diagnostic apparatus for the detection of cancer, genetic or heredity diseases

Classe 42

Providing temporary use of online non-downloadable software for use in collecting, organizing and managing data on bioinformatics, genomics, phenomics, microbiome, and metagenomics applications; hosting of computer databases featuring information relating to bioinformatics, genomics, phenomics, microbiome, metagenomics, organism- and pathogenspecific genotype records, and organism and pathogen-specific phenotype information; consulting relating to computer programming for acquiring, creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's disease profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; providing temporary use of on-line nondownloadable software and applications for genome analysis, developing personal treatment strategies for patients with diagnosed cancer and other diseases or disorders; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; providing information about medical and scientific research in the field of bioinformatics to enable physicians and healthcare professionals to optimize treatment in clinical practice; computer programming services for medical reporting, namely, for creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; scientific research services, namely, providing information relating to research in the field of specific molecular and genomic sciences for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients with cancer and other diseases and disorders

Classe 44

Providing medical information and medical advice in the fields of retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data and patient-specific data, molecular test results, clinical trial data; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols; medical consulting services in the field of genomics and biological sequence processing and analysis for medical diagnosis and treatment purposes; providing medical information for the purposes of medical diagnosis and treatment in the field of molecular genetics; identification and testing of DNA samples for health care purposes; health care services, namely, medical genomics and data science consultancy to provide optimal health and disease prevention or treatment to patients; providing health information relating to genetics and diagnostics via the Internet; bioinformatics analysis for medical diagnostic and personalized treatment purposes; nucleic acid analysis and screening for medical diagnostic and treatment purposes

Publicações

Histórico de despachos e eventos da marca no USPTO.

27 publicações encontradas

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

21/07/2025

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/12/2020

FICS

FINAL DISPOSITION NOTICE SENT TO IB

12/11/2020

FIMP

FINAL DISPOSITION PROCESSED

12/11/2020

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

21/10/2020

R.PR

REGISTERED-PRINCIPAL REGISTER

21/07/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

05/05/2020

PUBO

PUBLISHED FOR OPPOSITION

05/05/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

15/04/2020

ALIE

ASSIGNED TO LIE

02/04/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

25/03/2020

XAEC

EXAMINER'S AMENDMENT ENTERED

25/03/2020

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

25/03/2020

GNEA

EXAMINERS AMENDMENT E-MAILED

25/03/2020

CNEA

EXAMINERS AMENDMENT -WRITTEN

25/03/2020

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

05/03/2020

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/03/2020

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/03/2020

RFNT

REFUSAL PROCESSED BY IB

28/09/2019

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

06/09/2019

RFRR

REFUSAL PROCESSED BY MPU

06/09/2019

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

14/08/2019

CNRT

NON-FINAL ACTION WRITTEN

13/08/2019

MAFR

APPLICATION FILING RECEIPT MAILED

13/08/2019

DOCK

ASSIGNED TO EXAMINER

09/08/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

09/08/2019

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

01/08/2019

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace QIAGEN - SAMPLE TO OUTCOME ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.